Skip to main content
Figure 2 | Journal of Medical Case Reports

Figure 2

From: Five-year follow-up of Japanese patients with Paget's disease of the bone after treatment with low-dose oral alendronate: a case series

Figure 2

Changes in T-ALP level, uNTX level, and bone pain (VAS) after treatment with a low dose of alendornate for six months (Patient 1). (A) T-ALP and (B) uNTX levels returned to a normal range, and (C) bone pain (VAS) disappeared within six months. These remissions continued for the five years since the discontinuation of the treatment. T-ALP (IU/L), serum total alkaline phosphatase; uNTX (nMBCE/mM·CR), urinary N-terminal telopeptide of type I collagen; VAS, visual analogue scale; T, duration of the treatment with alendronate (0 to 6 months).

Back to article page